Disease-modifying Potential of Transdermal NICotine in Early Parkinson's Disease
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to demonstrate that transdermal nicotine treatment
retards disease progression as measured by change in total Unified Parkinson's Disease Rating
Scale (UPDRS)(part I, II, III)score between baseline and after 52 weeks of study treatment
plus two more months wash out (60 weeks).
Phase:
Phase 2
Details
Lead Sponsor:
James BOYD MD
Collaborators:
German Parkinson Society (DPG) German Parkinson Study Group (GPS) International Parkinson Fonds Germany GmbH Michael J. Fox Foundation for Parkinson's Research Parkinson Study Group (PSG) Philipps University Marburg Medical Center